About the clinical studies in GUIDE.MRD
There are currently three ongoing studies in the GUIDE.MRD project. They are focused on ctDNA diagnostics in Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), and Non-small Cell Lung Cancer (NSCLC).
The studies have the following aims:
- Compare the top-3 best-performing ctDNA diagnostics
- Observe how the ctDNA diagnostics perform at two different moments in the patient pathway:
- After surgery – this will help to understand which patients will benefit from additional treatment (also called adjuvant therapy)
- After treatment is completed – this will help to understand which patients may still need additional treatment (i.e. have minimal residual disease (MRD))
The studies also have similarities in how they are designed:
- They are observational studies, meaning the researchers do not assign participants to a treatment or other intervention and patient are treated according to the physician decision based on the relevant national guideline (Standard-of-Care).
- Participants are recruited prospectively, meaning people actively agree to participate and provide data and biological samples, and their treatment plans and health outcomes are tracked over time.
- Analysis of ctDNA in the studies is retrospective, meaning that it is conducted at the end of the study and does not guide clinical decision-making.
